Atopic Dermatitis

>

Latest News

FDA Expands Indication for Roflumilast Treat Atopic Dermatitis in Children Ages 2 to 5 Image Courtesy of Arcutis
FDA Expands Indication for Roflumilast to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

October 6th 2025

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group / image credit ©Waldenmarus/stock.adobe.com
FDA Approves Ruxolitinib for Pediatric Patients Aged 2-11 Years as First Topical JAK Inhibitor for the Age Group

September 19th 2025

OX40 Inhibitor Rocatinlimab Shows Significant Response in Combination with Topical Therapy for AD / image courtesy of Oregon Health and Sciences university - Eric Simpson, MD
OX40 Inhibitor Rocatinlimab Shows Significant Response in Combination with Topical Therapy for AD

September 19th 2025

Temtokibart Shows Promise in Phase 2b Trials in Adults With Moderate-to-Severe Atopic Dermatitis / image courtesy of Skin Health Institute
Temtokibart Shows Efficacy and Strong Biomarker Response in Phase 2b Trial for Atopic Dermatitis

September 18th 2025

Phase 3 Data Support Efficacy of Delgocitinib Cream in Adolescents With Chronic Hand Eczema; Pooled Analysis Confirms Safety in Adults
Phase 3 Data Support Efficacy of Delgocitinib Cream in Adolescents With Chronic Hand Eczema; Pooled Analysis Confirms Safety in Adults

September 18th 2025

More News

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment / image credit ©MichaelVI/stock.adobe.com

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

Grace Halsey
January 13th 2025

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Grace Halsey
January 10th 2025

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

Dermatologist Mona Shahriari, MD, Relies on Primary Care Colleagues as First-Line Prescribers for AD

Dermatologist Mona Shahriari, MD, Relies on Primary Care Colleagues as First-Line Prescribers for AD

Mona Shahriari, MD;Grace Halsey
October 30th 2024

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

<12345
© 2025 MJH Life Sciences

All rights reserved.